KalVista Pharmaceuticals (KALV) said Tuesday its namesake unit has licensed commercialization rights for the sebetralstat experimental treatment for hereditary angioedema in Japan to Kaken Pharmaceutical.
The company will receive an upfront payment of $11 million, with an additional payment of up to $11 million, subject to a regulatory milestone expected early next year. KalVista said it's also eligible for commercial milestone payments, plus certain sale royalties.
Hereditary angioedema is a disorder that leads to recurrent attacks of severe swelling.
KalVista shares were up 3.5% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.